A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain.
← catalyst calendarNCT06075615 · readout in 19 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Withdrawn
Study type
Observational
Enrollment
0actual
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Sponsor Decision
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-09-30 | estimated | When the study began enrolling |
| Primary completion | 2026-09-07 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-09-07 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-02-07 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Carcinoma, Non-Small-Cell Lung
Intervention
- Drug: dacomitnib
Primary outcomes
what the primary-completion date above is the date OFThe real-world intracranial overall response rate (rwICORR) at Month 3
measured 3 months from first dose of dcomitnib
The real-world intracranial overall response rate (rwICORR) at Month 6
measured 6 months from first dose of dacomitnib
The real-world intracranial overall response rate (rwICORR) at Month 12
measured 12 months from first dose of dacomitinib
The real-world intracranial clinical benefit rate (rwICBR) at Month 3
measured 3 months from first dose of dacomitinib
The real-world intracranial clinical benefit rate (rwICBR) at Month 6
measured 6 months from first dose of dacomitinib
The real-world intracranial clinical benefit rate (rwICBR) at Month 12
measured 12 months from first dose of dacomitinib
The real-world intracranial time to progression (rwICTTP)
measured 30 months from first dose of dacomitinib
The real-world systemic overall response rate (rwORR) at Month 3
measured 3 months from first dose of dacomitinib
The real-world systemic overall response rate (rwORR) at Month 6.
measured 6 months from first dose of dacomitinib
The real-world systemic overall response rate (rwORR) at Month 12.
measured 12 months from first dose of dacomitinib
The real-world progression-free survival (rwPFS) during 12 months from index date
measured 12 months from index date
The real-world overall survival (rwOS) during 12 months from index date
measured 12 months from index date
The real-world overall survival (rwOS) during 24 months from index date
measured 24 months from index date
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed